IgGenix, Inc. is a clinical-stage biotechnology company focused on the discovery and development of innovative antibody therapies aimed at addressing allergies and other immunological diseases. Central to their approach is the SEQ SIFTER™ antibody discovery platform, which utilizes single-cell RNA sequencing to identify and isolate rare human B cells that produce IgE antibodies from blood samples. This technology enables IgGenix to engineer fully human, high-affinity IgG antibodies that specifically target allergens, effectively blocking the allergic cascade. Their lead candidate, IGNX001, is designed to treat peanut allergies by directly inhibiting the immune response associated with allergic reactions.

The company is actively conducting clinical trials, including the ACCELERATE Peanut Study, which evaluates the safety and tolerability of IGNX001. IgGenix's research pipeline includes multiple programs targeting various food and environmental allergies, demonstrating their commitment to advancing therapeutic options for patients suffering from these conditions. By leveraging their deep understanding of molecular immunology and innovative antibody engineering, IgGenix aims to provide effective treatments that empower individuals to live without the fear of life-threatening allergic reactions.

United States

IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

IgGenix

Company Details